Conference Summaries: Day Three<BR> Tuesday, July 10, 2001

The Body Covers: The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment

Conference Summaries: Day Three
Tuesday, July 10, 2001

Invited Lecture
- Mother-to-Child Transmission: What Have We Learned? (Abstract IL5)
  Coverage by Andrew T. Pavia, M.D.
Plenary Lectures
- Immune Reconstitution: Translating Immunologic Knowledge into Therapy (Abstract PL8)
  Coverage by Calvin J. Cohen, M.D., M.S.
- The Next Target in Therapy: Viral Entry (Abstract PL9)
  Coverage by Calvin J. Cohen, M.D., M.S.
Antiretroviral Therapy
- Greater Suppression of CD8 Activation with Four vs. Three Drugs in Early Stages of Primary HIV Infection (PHI) Despite Similar Plasma Virological Decay Rates (Abstract 61)
  Coverage by Howard Grossman, M.D.
- Abacavir/Combivir (ABC/COM) Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (Abstract 63)
  Coverage by Alvan Fisher, M.D.
Toxicities of HAART
Therapies Directly Targeting the Immune System
- Intermittent IL-2 Administration in HIV Infected Patients Leads to a Decrease in CD4+ T Cell Turnover Rates (Abstract 103)
  Coverage by Brian A. Boyle, M.D., J.D.
Salvage Therapy
- Impact of Treatment Interruption on Plasma Viral Load, CD4 Count and Virtual Phenotypes (Virco) in HIV Patients Who Failed Multiple Courses of Antiretroviral Therapy (Abstract 111)
  Coverage by Howard Grossman, M.D.
- Antiviral Activity and Tolerability of PEG-Intron in HIV Patients Failing HAART (Abstract 115)
  Coverage by Howard Grossman, M.D.
IAS-USA Panel
- When to start Antiretroviral Therapy; Considerations in Choosing an Initial Regimen; When to Change Regimens; Options for Managing Failure (Panel IS1)
  Coverage by Pablo Tebas, M.D.
Antiretroviral Therapy II
- HIV NAT 002.1/002.2: Immediate (IS) Versus Deferred Switching (DS) from ddI/D4T to AZT/3TC in an HIV+ Thai Population and Determine Predictors to Improve Treatment Response to Long-Term Dual Nucleoside Therapy as an Option for Resource-Limited Countries (Poster 415)
  Coverage by Alvan Fisher, M.D.
Lipodystrophy
Hyperlactatemia and Other Toxicities
- Risk Factor Analysis of Hypersensitivity Reactions to Abacavir: Retrospective Analysis of 25 Clinical Trials (Poster 527)
  Coverage by Brian A. Boyle, M.D., J.D.
Resistance

Previous Day's Sessions | Next Day's Sessions

Return to The Body's coverage of
The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.